Results 71 to 80 of about 31,380 (219)

Hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease: A real‐world study in Quebec

British Journal of Haematology, EarlyView.
Summary Haemoglobin SC (HbSC) disease is the second most prevalent form of sickle cell disease, but evidence for hydroxyurea (hydroxycarbamide; HU) to prevent pain episodes was limited until the prospective identification of variables as outcomes for treatment (PIVOT) trial.
Alice Girard, Laurianne Charette, Mélissa Haouchine, Laurence Bozec, Mohamed Zakaria Bachir Bouyadjera, Mariane Poitras, Vincent‐Thierry Taillefer, Chloé Trudeau, Yves Pastore, Nathalie Letarte, Stéphanie Forté   +10 more
wiley   +1 more source

Hydroxyurea (hydroxycarbamide) in haemoglobin SC disease: Moving from therapeutic hesitation to evidence‐guided care

British Journal of Haematology, EarlyView.
Girard et al. report a retrospective, single‐centre, real‐world study evaluating hydroxyurea (hydroxycarbamide) use in adults with haemoglobin SC disease in Quebec. Hydroxyurea was associated with reduced vaso‐occlusive crisis composite events, mostly mild adverse events and no observed hyperviscosity‐related complications, while highlighting adherence
Tahereh Setayesh
wiley   +1 more source

Role of hydroxyurea therapy in the prevention of organ damage in sickle cell disease: a systematic review and meta-analysis

Systematic Reviews
Background Hydroxyurea is an affordable drug that reduces vaso-occlusive crises and transfusion requirements in sickle cell disease. However, its effectiveness in preventing chronic organ damage is still unclear.
Naveen Khargekar, Anindita Banerjee, Shreyasi Athalye, Namrata Mahajan, Neha Kargutkar, Prashant Tapase, Manisha Madkaikar   +6 more
doaj   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Effect of Combined Hydroxyurea and Chelation Therapy in Reducing Serum Ferritin Level, Liver and Spleen Size in Transfusion Dependent Thalassaemia Major Patients.

Journal of Rawalpindi Medical College, 2019
Background: To compare hydroxyurea plus iron chelation therapy with iron chelation therapy alone in controlling iron overload in children with beta thalassaemia major.
Tatheer Zahra, Wajeeha Amber, Itrat Fatima   +2 more
doaj  

A Pharmacist-Managed Hydroxyurea Prescribing Protocol Improves Uptake and Optimization among Patients with Sickle Cell Disease

Advances in Hematology
Sickle cell disease (SCD) is a common genetic disorder with potentially serious sequelae that can be effectively treated with hydroxyurea. Despite its favorable benefit-risk profile, hydroxyurea uptake in patients with SCD is low.
Cameron Roessner, Trudy Sale, Kelsey Uminski, Dawn Goodyear, Natalia Rydz   +4 more
doaj   +1 more source

Predict less, prevent more: A familiar mantra for sickle cell anaemia?

British Journal of Haematology, EarlyView.
Commentary on: Sommet J, Boizeau P, Haouari Z, et al. Identification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia. Br J Haematol. 2026 (Online ahead of print). doi: 10.1111/bjh.70726.
Charles T. Quinn
wiley   +1 more source

Hydroxyurea-Induced Hypersensitivity Pneumonitis: A Case Report and Literature Review

Canadian Respiratory Journal, 2000
Hydroxyurea is a cytotoxic agent indicated in the treatment of a variety of malignant and nonmalignant conditions. Apart from dose-related bone marrow suppression, this antineoplastic agent is generally well tolerated.
Harminder S Sandhu, Penny J Barnes, Paul Hernandez   +2 more
doaj   +1 more source

Hydroxyurea Therapy in Thalassemia^a

Annals of the New York Academy of Sciences, 1998
Abstract: The clinical effectiveness of Hydroxyurea in thalassemia is still controversial. The present paper puts together the authors' experience in two groups of patients with thalassemia intermedia and sickle cell/β‐thalassemia treated with varying dosages of hydroxyurea over several months. A third group received hydroxyurea along with recombinant
Loukopoulos, D., Voskaridou, E., Stamoulakatou, A., Papassotiriou, Y., Kalotychou, V., Loutradi, A., Cozma, G., Tsiarta, H., Pavlides, N.   +8 more
openaire   +3 more sources

Identification of predictive factors for reversal of cerebral vasculopathy in an original longitudinal cohort study in newborns with sickle cell anaemia

British Journal of Haematology, EarlyView.
Summary Cerebral macrovasculopathy (CV) is a major complication in children with sickle cell anaemia (SCA) and usually requires a long‐term transfusion programme (TP) to prevent stroke. This study aimed to identify factors predicting reversal of CV on TP in a single‐centre newborn cohort. Among 375 patients, 50 presented CV and received TP.
Julie Sommet, Priscilla Boizeau, Zinedine Haouari, Berengère Koehl, Monique Elmaleh, Emmanuelle Lesprit, Florence Missud, Ghislaine Ithier, Laurent Holvoet, Valentine Brousse, Christophe Delclaux, André Denjean, Suzanne Verlhac, Corinne Alberti, André Baruchel, Nathalie Couque, Malika Benkerrou   +16 more
wiley   +1 more source